KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.

MLA

Kaddu-Mulindwa, Dominic, et al. “KIR2DS1-HLA-C Status as a Predictive Marker for Benefit from Rituximab: A Post-Hoc Analysis of the RICOVER-60 and CLL8 Trials.” The Lancet. Haematology, vol. 9, no. 2, Feb. 2022, pp. e133–42. EBSCOhost, https://doi.org/10.1016/S2352-3026(21)00369-0.

APA

Kaddu-Mulindwa, D., Altmann, B., Robrecht, S., Ziepert, M., Regitz, E., Tausch, E., Held, G., Poeschel, V., Lesan, V., Bittenbring, J. T., Thurner, L., Pfreundschuh, M., Christofyllakis, K., Truemper, L., Loeffler, M., Schmitz, N., Hoth, M., Hallek, M., Fischer, K., … Rixecker, T. M. (2022). KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. The Lancet. Haematology, 9(2), e133–e142. https://doi.org/10.1016/S2352-3026(21)00369-0

Chicago

Kaddu-Mulindwa, Dominic, Bettina Altmann, Sandra Robrecht, Marita Ziepert, Evi Regitz, Eugen Tausch, Gerhard Held, et al. 2022. “KIR2DS1-HLA-C Status as a Predictive Marker for Benefit from Rituximab: A Post-Hoc Analysis of the RICOVER-60 and CLL8 Trials.” The Lancet. Haematology 9 (2): e133–42. doi:10.1016/S2352-3026(21)00369-0.